Methadone as a Cytochrome P450 Inhibitor
Yes, methadone does inhibit certain cytochrome P450 enzymes, most notably CYP2D6 and potentially CYP3A4, though it is primarily a substrate rather than a clinically significant inhibitor of most CYP enzymes.
Methadone's Role: Primarily a CYP Substrate
The FDA drug label clearly establishes that methadone is metabolized by (not an inhibitor of) multiple CYP enzymes 1. Specifically, methadone undergoes hepatic N-demethylation primarily via:
- CYP3A4 (principal enzyme)
- CYP2B6 (principal enzyme)
- CYP2C19 (principal enzyme)
- CYP2C9 (lesser extent)
- CYP2D6 (lesser extent)
This means methadone is vulnerable to drug interactions when combined with CYP inducers (which accelerate its metabolism and may cause withdrawal) or CYP inhibitors (which slow its metabolism and may cause toxicity) 1.
Evidence for Methadone as an Inhibitor
CYP2D6 Inhibition (Clinically Relevant)
Methadone does inhibit CYP2D6 in vivo, despite not being a substrate of this enzyme 2. A 2012 study demonstrated that methadone-maintained patients had:
- Significantly impaired CYP2D6-mediated O-demethylation of codeine (metabolic ratio 2.8 ± 3.1 vs. 0.60 ± 0.43 in buprenorphine controls, P=0.0044)
- Reduced formation of morphine-6-glucuronide (the active analgesic metabolite)
- This inhibition occurred even though methadone is not metabolized by CYP2D6 2
Clinical implication: Patients on methadone may have reduced analgesic response to codeine and tramadol (both CYP2D6-dependent prodrugs) 3.
CYP3A4 Inhibition (Moderate, In Vitro)
A 1997 in vitro study showed methadone inhibits CYP3A4-mediated nifedipine oxidation with a Ki of 100 μM through mixed-type inhibition 4. However, this is a moderate inhibitory effect and the clinical significance is limited compared to methadone's role as a CYP3A4 substrate.
UGT2B7/2B4 Inhibition
Methadone also inhibits UGT2B7 and UGT2B4 glucuronidation pathways in vivo 2, which affects the metabolism of drugs dependent on these enzymes.
Clinical Management Algorithm
When Prescribing Methadone:
Avoid combining with CYP2D6 prodrugs (codeine, tramadol) as methadone will reduce their conversion to active metabolites and diminish analgesia 3, 2
Monitor for methadone toxicity when adding CYP3A4/2B6/2C19 inhibitors:
Anticipate withdrawal when adding CYP inducers:
- Rifampin, phenytoin (causes ~50% reduction in methadone exposure), carbamazepine, St. John's Wort 1
- May require methadone dose increase or more frequent dosing
Methadone should only be prescribed by experienced clinicians due to its complex pharmacokinetics 5
Key Caveats
- Genetic polymorphisms matter: CYP2B6*6/*6 carriers have significantly reduced methadone clearance and higher plasma concentrations, increasing toxicity risk 6, 7
- The half-life varies widely (7-59 hours), making dose adjustments unpredictable 1
- Methadone's lipophilic nature causes tissue accumulation, prolonging effects beyond plasma levels 1
- Pregnancy increases methadone clearance, potentially requiring dose increases 1
Bottom line: While methadone is predominantly a CYP substrate (making it vulnerable to interactions), it does clinically inhibit CYP2D6 and UGT enzymes, which must be considered when combining with other medications metabolized by these pathways.